75922-48-4

Usage

Uses

Used in Pharmaceutical Industry:
1,3-DIETHYL-8-PHENYLXANTHINE is used as a selective A1 adenosine receptor antagonist for its binding activity, which makes it a potential candidate for the development of drugs targeting adenosine receptors. Its high selectivity for the A1 receptor over the A2 receptor (with IC50 values of 135 nM and 5300 nM, respectively) indicates its potential use in treating conditions where A1 adenosine receptor modulation is desired.

InChI:InChI=1/C15H16N4O2/c1-3-18-13-11(14(20)19(4-2)15(18)21)16-12(17-13)10-8-6-5-7-9-10/h5-9H,3-4H2,1-2H3,(H,16,17)

Upstream product

• 52998-22-8 5,6-diamino-1,3-diethyluracil 
• 100-52-7 benzaldehyde 

Relevant academic research and scientific papers

An efficient route to xanthine based A2A adenosine receptor antagonists and functional derivatives

A one-pot route to 8-substituted xanthines has been developed from 5,6-diaminouracils and carboxaldehydes. Yields are good and the process applicable to a range of substrates including a family of A2A adenosine receptor antagonists. A new route to the KW-6002 family of antagonists is presented including a pro-drug variant, and application to related image contrast agents developed.

Synthesis of 8-substituted xanthines via 5,6-diaminouracils: an efficient route to A2A adenosine receptor antagonists

A one-pot route to 8-substituted xanthines has been developed from 5,6-diaminouracils and carboxaldehydes. The process, promoted by (bromodimethyl)sulfonium bromide, is mild and efficient and eliminates the need for external oxidants. Yields are good and the process is applicable to a range of substrates including a family of A2A adenosine receptor antagonists. Preparation of a new analog of the antagonist KW-6002 is presented, and in situ bromination of aryl substituted products demonstrated.